Mesoblast share price logo

Mesoblast Share Price

NASDAQ: MESO

Small Cap

$14.77

+0.14

(+0.96%)

as on

Mesoblast Stock Performance

as on March 20, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $14.33
    $14.80
    downward going graph

    2.98%

    Downside

    0.20%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $9.61
    $21.50
    downward going graph

    34.94%

    Downside

    45.57%

    Upside

    downward going graph

Mesoblast share price movements today

Previous Close
$14.63
Open
$14.42
Volume
302.1K
Day's Low - High
$14.33 - $14.80
52 Week Low - High
$9.61 - $21.50

Mesoblast Historical Returns

1 Month Return
-12.44 %
3 Month Return
-24.13 %
1 Year Return
+ 8.08 %
3 Year Return
+ 133.86 %
5 Year Return
-20.79 %

Mesoblast Stock Fundamentals & Key Indicators

Check Mesoblast market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.9B

EPS (TTM)

-0.2767

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-58.2M

Revenue (TTM)

17.2M

Profit Margin

0.00%

Return On Equity TTM

-18.95%

Mesoblast vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Mesoblast with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Mesoblast image
Mesoblast
BUY$1.9B-20.79%NA0.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.7B115.8%135.118.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$114.7B111.95%29.532.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$32.4BNA114.755.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$78.7B55.68%17.9531.41%

Stock Returns calculator for Mesoblast Stock including INR - Dollar returns

The Mesoblast stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Mesoblast investment value today

Current value as on today

₹1,15,930

Returns

₹15,930

(+15.93%)

Returns from Mesoblast Stock

₹7,968 (+7.97%)

Dollar Returns*

₹7,962 (+7.96%)

Analyst Recommendation on Mesoblast Stock

Based on 9 analysts

BUY

77.78%

Buy

22.22%

Hold

0.00%

Sell

Based on 9 analysts, 77.78% of analysts recommend a 'BUY' rating for Mesoblast. Average target price of $35

Mesoblast Share Price Target

Get share price movements and forecasts by analysts on Mesoblast.

What analysts predicted

57.8%UPSIDE

Target Price

$35

Current Price

$14.77

Analyzed by

9 Analysts

Target

$35.00

Mesoblast target price $35, a slight upside of 57.8% compared to current price of $14.77. According to 9 analysts rating.

Mesoblast Stock’s Investor Sentiment and Interest

Search interest for Mesoblast Stock has decreased by -24% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-24% versus previous 30 day period

Mesoblast Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
1
2
1
1
1
1
1
1
7
7
Gross Profit
-11
-13
-8
-8
-9
-9
-1
-1
-16
-16
Operating Income
-14
-19
-20
-20
-22
-22
-20
-20
-34
-34
EBITDA
-12
-17
-12
-12
-15
-15
-9
-9
-19
-19
Interest Expense
4
3
5
5
4
4
5
5
-
-
Depreciation
0
0
-
-
-
-
-
-
-
-
Income Before Tax
-18
-21
-16
-16
-27
-27
-23
-23
-27
-27
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-18
-21
-16
-16
-27
-27
-23
-23
-27
-27
Net Profit Margin
-959.26%
-1024.73%
-960.42%
-960.42%
-2204.34%
-2204.34%
-1518.82%
-1518.82%
-386.04%
-386.04%

Mesoblast Annual Profit & Loss

All numbers in Millions USD

Jun 2016
Jun 2017
Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Jun 2023
Jun 2024
Jun 2025
Total Revenue
42
2
17
16
32
7
10
7
5
17
Gross Profit
12
-9
11
-58
-49
-78
-53
-47
-35
12
Operating Income
-55
-90
-77
-80
-74
-109
-80
-69
-84
-62
EBITDA
-28
-87
-74
-84
-68
-84
-76
-58
-56
-73
Interest Expense
9
-
1
11
14
10
17
19
20
22
Depreciation
-
3
2
2
3
4
4
4
4
6
Income Before Tax
-90
-90
-65
-98
-87
-99
-91
-82
-88
-101
Income Tax Expense
-86
-13
-30
-8
-9
0
0
0
0
0
Net Income
-4
-76
-35
-89
-77
-98
-91
-81
-87
-102
Net Profit Margin
-9.70%
-3184.70%
-203.51%
-537.01%
-242.38%
-1325.25%
-894.59%
-1091.71%
-1490.27%
-593.92%

Mesoblast Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-16
-
-
-
-23
-
-27
-
-
Operating Cash Flow
-13
-
-
-10
-10
-12
-16
-14
-15
Investing Cash Flow
0
0
0
0
0
0
0
0
0
Financing Cash Flow
34
11
-3
-1
-2
156
-4
-1
0
Change in Cash
24
-1
-13
-11
-13
144
-20
-16
-14

Mesoblast Annual Cash Flow

All numbers in Millions USD

Jun 2017
Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Jun 2023
Jun 2024
Jun 2025
Net Income
-76
-35
-89
-77
-98
-91
-81
-87
-102
Operating Cash Flow
-95
-75
-57
-56
-106
-65
-63
-48
-49
Investing Cash Flow
0
-1
-1
-3
-1
0
0
0
0
Financing Cash Flow
60
68
71
137
114
-9
74
40
147
Change in Cash
-35
-7
12
78
7
-76
10
-8
98

Global Institutional Holdings in Mesoblast

Funds
Holdings
Summit X, LLC
0.16%
Citigroup Inc
0.02%
Susquehanna International Group, LLP
0.21%
BlackRock Inc
0.42%
Morgan Stanley - Brokerage Accounts
0.36%
See all

Insights on Mesoblast

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, MESO has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 5 quarters, 1.25M → 7.02M (in $), with an average increase of 24.5% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, MESO stock has moved up by 133.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 22.7% return, outperforming this stock by 14.6%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -23.96M → -27.10M (in $), with an average decrease of 6.5% per quarter

About Mesoblast

mesoblast; (asx: msb; nasdaq:meso) is a world leader in innovative cell-based medicines. we have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells (mlcs) to establish what we believe is the most advanced cellular medicines portfolio in the industry. our ‘off-the-shelf’ products are allogeneic - meaning cells from one donor may be used in many different recipients without the need for matching. our licensee in japan has launched its mlc-based product for acute graft versus host disease in children and adults in japan. it is the first allogeneic cell-based product in japan to be fully approved in japan. we believe we are well positioned to have the first industrially manufactured allogeneic cell-based product approved in the united states. our lead product candidates under investigation are: • mpc-150-im for chronic heart failure • mpc-06-id for chronic low back pain due to disc degeneration • msc-100-iv for acute graf
OrganisationMesoblast
Headquarters55 Collins Street, Melbourne, VIC, Australia, 3000
IndustryHealth Technology
CEODr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
E-voting on sharesClick here to vote

Key Management of Mesoblast

Name

Title

Ms. Teresa Montagut M.D., Ph.D.

Head of Clinical Development & Medical Affairs

Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)

Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director

Mr. James Michael O'Brien CPA, M.B.A.

Chief Financial Officer

Mr. Peter T. Howard B.Sc., L.L.B.

General Counsel & Corporate Executive

Ms. Geraldine Storton B.Sc., M.B.A., MMS

Head of Regulatory Affairs & Quality Management

Dr. Fiona See Ph.D.

Senior VP & Head of Translational Research

Mr. Marcelo Santoro

Chief Commercial Officer

Dr. Eric A. Rose M.D.

Chief Medical Officer & Executive Director

Dr. Paul J. Simmons BSc, Ph.D.

Scientific Advisor to the Chief Executive Officer

Mr. Justin Horst B.S.

Head of Manufacturing

FAQs

What is Mesoblast share price today?

Mesoblast share price today is $14.77 as on at the close of the market. Mesoblast share today touched a day high of $14.8 and a low of $14.33.

What is the 52 week high and 52 week low for Mesoblast share?

Mesoblast share touched a 52 week high of $21.5 on and a 52 week low of $9.61 on . Mesoblast stock price today i.e. is closed at $14.77,which is 31.30% down from its 52 week high and 53.69% up from its 52 week low.

What is Mesoblast's market capitalisation today?

Mesoblast market capitalisation is $0.00T as on .

How to invest in Mesoblast Stock (MESO) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Mesoblast on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Mesoblast Shares that will get you 0.1016 shares as per Mesoblast share price of $14.77 per share as on March 20, 2026 at 1:29 am IST.

What is the minimum amount required to buy Mesoblast Stock (MESO) from India?

Indian investors can start investing in Mesoblast (MESO) shares with as little as ₹93.193 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹931.93 in Mesoblast stock (as per the Rupee-Dollar exchange rate as on ). Based on Mesoblast share’s latest price of $14.77 as on March 20, 2026 at 1:29 am IST, you will get 0.6770 shares of Mesoblast. Learn more about fractional shares .

What are the returns that Mesoblast has given to Indian investors in the last 5 years?

Mesoblast stock has given -20.79% share price returns and 27.41% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?